Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Inc. (Nasdaq: CMND) has filed an international patent application for innovative psychedelic compounds designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. This application is part of Clearmind's collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The compounds were invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel.
The global PTSD treatment market, valued at $16.8 billion in 2023, is projected to reach $27.37 billion by 2033. Current PTSD treatments offer efficacy, and FDA-approved drugs often come with side effects. Clearmind aims to develop effective and safe next-generation psychedelic compounds to significantly improve patients' quality of life.
Clearmind Medicine Inc. (Nasdaq: CMND) ha presentato una domanda di brevetto internazionale per composti psichedelici innovativi progettati per trattare il disturbo da stress post-traumatico (PTSD) e altre condizioni di salute mentale. Questa domanda fa parte della collaborazione di Clearmind con la Yissum Research Development Company dell'Università Ebraica di Gerusalemme. I composti sono stati inventati dai professori Rami Yaka, Ahmed Masaewa e Avi Priel.
Il mercato globale per il trattamento del PTSD, valutato 16,8 miliardi di dollari nel 2023, è previsto raggiungere 27,37 miliardi di dollari entro il 2033. I trattamenti attuali per il PTSD offrono efficacia, e i farmaci approvati dalla FDA spesso comportano effetti collaterali. Clearmind si propone di sviluppare composti psichedelici di nuova generazione, efficaci e sicuri, per migliorare significativamente la qualità della vita dei pazienti.
Clearmind Medicine Inc. (Nasdaq: CMND) ha presentado una solicitud de patente internacional para compuestos psicodélicos innovadores diseñados para tratar el trastorno de estrés postraumático (TEPT) y otras condiciones de salud mental. Esta solicitud forma parte de la colaboración de Clearmind con la Yissum Research Development Company de la Universidad Hebrea de Jerusalén. Los compuestos fueron inventados por los profesores Rami Yaka, Ahmed Masaewa y Avi Priel.
El mercado global de tratamientos para el TEPT, valorado en 16.8 mil millones de dólares en 2023, se proyecta que alcanzará 27.37 mil millones de dólares para 2033. Los tratamientos actuales para el TEPT ofrecen eficacia, y los medicamentos aprobados por la FDA a menudo tienen efectos secundarios. Clearmind tiene como objetivo desarrollar compuestos psicodélicos de nueva generación que sean efectivos y seguros para mejorar significativamente la calidad de vida de los pacientes.
Clearmind Medicine Inc. (Nasdaq: CMND)는 외상 후 스트레스 장애 (PTSD)와 기타 정신 건강 상태를 치료하기 위해 설계된 혁신적인 환각 화합물에 대한 국제 특허 출원을 했습니다. 이 출원은 Clearmind가 예루살렘 히브리대학교의 Yissum Research Development Company와 협력한 일환입니다. 이 화합물은 Rami Yaka, Ahmed Masaewa 및 Avi Priel 교수에 의해 발명되었습니다.
2023년 168억 달러로 평가된 글로벌 PTSD 치료 시장은 2033년까지 273억 7천만 달러에 도달할 것으로 예상됩니다. 현재 PTSD 치료는 효능을 제공하나 FDA 승인 약물은 종종 부작용이 동반됩니다. Clearmind는 환자들의 삶의 질을 현저하게 향상시키기 위해 효과적이고 안전한 차세대 환각 화합물을 개발하는 것을 목표로 하고 있습니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a déposé une demande de brevet international pour des composés psychédéliques innovants conçus pour traiter le trouble de stress post-traumatique (TSPT) et d'autres troubles mentaux. Cette demande fait partie de la collaboration de Clearmind avec la Yissum Research Development Company de l'Université hébraïque de Jérusalem. Les composés ont été inventés par les professeurs Rami Yaka, Ahmed Masaewa et Avi Priel.
Le marché mondial du traitement du TSPT, évalué à 16,8 milliards de dollars en 2023, devrait atteindre 27,37 milliards de dollars d'ici 2033. Les traitements actuels du TSPT offrent une efficacité, et les médicaments approuvés par la FDA sont souvent accompagnés d'effets secondaires. Clearmind vise à développer des composés psychédéliques de nouvelle génération qui soient à la fois efficaces et sûrs, afin d'améliorer considérablement la qualité de vie des patients.
Clearmind Medicine Inc. (Nasdaq: CMND) hat einen internationalen Patentantrag für innovative psychedelische Verbindungen eingereicht, die zur Behandlung von posttraumatischer Belastungsstörung (PTBS) und anderen psychischen Erkrankungen entwickelt wurden. Dieser Antrag ist Teil der Zusammenarbeit von Clearmind mit der Yissum Research Development Company der Hebräischen Universität Jerusalem. Die Verbindungen wurden von den Professoren Rami Yaka, Ahmed Masaewa und Avi Priel erfunden.
Der globale Markt für PTBS-Behandlungen, der 2023 mit 16,8 Milliarden US-Dollar bewertet wurde, wird voraussichtlich bis 2033 auf 27,37 Milliarden US-Dollar wachsen. Die derzeit verfügbaren PTBS-Behandlungen bieten Wirksamkeit, und von der FDA zugelassene Medikamente haben häufig Nebenwirkungen. Clearmind zielt darauf ab, effektive und sichere psychodelische Verbindungen der nächsten Generation zu entwickeln, um die Lebensqualität der Patienten erheblich zu verbessern.
- Filing of international patent application for innovative psychedelic compounds to treat PTSD
- Collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem
- Potential to address a growing market, projected to reach $27.37 billion by 2033
- Aim to develop more effective and safer treatments for PTSD compared to current options
- None.
Insights
The filing of an international patent application for novel psychedelic compounds targeting PTSD treatment is a significant step for Clearmind Medicine and Yissum. This development addresses a critical gap in the
The potential impact of these compounds could be substantial, especially for moderate to severe PTSD cases where pharmacological options are scarce. If successful, these next-generation psychedelics could offer a more effective and safer alternative to current treatments, potentially revolutionizing PTSD therapy and capturing a significant market share.
However, it's important to note that patent filing is just an early step. The road from patent to marketable drug is long and fraught with challenges, including clinical trials and regulatory approvals. Investors should monitor the progress of these compounds through the development pipeline for a clearer picture of their potential market impact.
Clearmind Medicine's patent application represents a strategic move to strengthen its intellectual property portfolio in the rapidly growing psychedelic therapeutics market. With the global PTSD treatment market expected to grow at a CAGR of
The collaboration with Yissum, leveraging the expertise of renowned researchers, enhances Clearmind's credibility and research capabilities. This could attract investor interest and potentially lead to partnerships with larger pharmaceutical companies, which is common in the biotech sector for clinical-stage companies.
However, investors should be cautious. The company's success hinges on the outcomes of future clinical trials and regulatory approvals. The psychedelic therapeutics sector, while promising, is still nascent and faces regulatory hurdles. Clearmind's financial stability and its ability to fund the lengthy and expensive drug development process will be important factors to watch in the coming years.
Innovative compounds designed to address critical unmet needs in PTSD treatment
Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the International Patent Cooperation Treaty (“PCT”). This submission is part of the Company’s ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”), pursuant to the exclusive licensing agreement Clearmind holds with Yissum.
The patent application covers innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel of the Hebrew University. These novel compounds are designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions.
The global market for PTSD treatment, valued at
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “Our collaboration with Yissum continues to yield remarkable results. We are proud of the groundbreaking innovations we are developing together to meet the growing demand for advanced treatments for various mental health conditions, including PTSD. This is particularly critical for moderate to severe cases of PTSD, where pharmacological options are limited, with only two FDA-approved agents available and other treatments used off-label. However, these drugs are often associated with side effects, such as nausea, weight gain, sexual dysfunction, insomnia, and increased anxiety. Our goal is to deliver effective and safe treatments for PTSD, such as our next-generation psychedelic compounds, which aim to significantly improve the quality of life for patients.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock
About Yissum
Yissum is the technology transfer company of the Hebrew University of Jerusalem. Founded in 1964, Yissum serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. The company has registered more than 11,680 patents globally, licensed over 1,160 technologies, and has spun out over 260 companies. Yissum’s business partners span the globe. For further information please visit www.yissum.co.il.
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the remarkable innovations it is developing with Yissum that are addressing the growing market demand for cutting-edge treatments aimed at a variety of mental health conditions, including PTSD, and its commitment is to bring effective and safe treatment for PTSD that aims to significantly improve quality of life for these patients. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the purpose of Clearmind Medicine's (CMND) recent patent application?
Who are the inventors of the compounds in Clearmind Medicine's (CMND) patent application?
What is the projected value of the global PTSD treatment market by 2033?
What are the limitations of current PTSD treatments that Clearmind Medicine (CMND) aims to address?
